CD19 and systemic sclerosis: The first promising experience with CD19-targeted CAR-T cells in diffuse cutaneous systemic sclerosis (SSc) was reported in a 60-year-old man, who exhibited rapid improvement in heart function, as assessed by 68Ga-FAPI-04 PET-CT, joint health from MRI, and skin fibrosis, alongside seroconversion of antinuclear antibody (ANA) and anti-RNA polymerase III autoantibodies, as well as stable lung function parameters (121).